Abstract # 2303 A Pretreatment PSA Level of 7 to 10 Ng/ml is an Independent Predictor of Adverse Biochemical Disease Free Survival among Low Risk Prostate Cancer Patients Treated with I-125 Brachytherapy

Presenter: Cesaretti, Jamie

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos

The six‐year bDFS rate for the entire cohort using the Phoenix definition was 93.0%. For patients with a PSA of 7.00 ng/ml or less, the six‐year bDFS was 96.28%. For patients with a PSA between 7.01 ng/ml and 10.0 ng/ml, the bDFS was 86.36%. (p=0.002). Both D90 and PSA level as continuous variables on multivariable analysis were significant for predicting bDFS (p=0.01 and p=0.01). A PSA level of greater than 7.01 ng/ml as a dichotomous variable was predictive of bDFS (p=0.004) in addition to D90 (p=0.02) on multivariable analysis. When the 32 patients with a D90 of less than 140 Gy were censored from analysis, only PSA was an independent predictor of outcome (p=0.002).